elapsed_time: 18s
was_input_captured: False
original_text: |
    Have relapsed or progressed after prior anti- PD-(L)1 therapy as follows:
    At least 12 weeks of treatment with only 1 line of anti-PD-(L)1 therapy (mono or combo) in the metastatic setting, without concomitant chemotherapy OR
    At least 12 weeks of single-agent durvalumab
inclusion: True
